nextcure.com - NXTC Income before deduction of interest, taxes and amortization

Graphic logo of NextCure Inc (NXTC)

NextCure, Inc. is recognized as a pioneer in discovering new biological pathways for immune activation. Its expert status is confirmed by absolute EBITDA, where the figure stands at 0.00, illustrating a path toward a commercial monopoly through patent assets. High future margins are ensured by massive demand for fresh therapeutic targets and licensing deals with pharma behemoths.

Profit before payment of interest, taxes and amortization: NextCure, Inc. (NXTC) for 11/23/2025 - 11/10/2026

NextCure - analytical breakdowns and key metrics (NXTC)

- market value and analyst target forecast:
Market Price NextCure Corporation|NXTC - Consensus Target
- issuer market value details:
Market Value NextCure|NXTC - Enterprise Value
- book capitalization information:
Net Assets per Share NextCure|NXTC - Company Book Value|Market Cap to Net Assets Ratio nextcure.com|NXTC - Aggregate Company Assets
- business debt structure and liquidity details:
Total Debt to Equity Ratio NextCure, Inc.|NXTC - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital NextCure Inc|NXTC - Company Debts|Debt to Book Value Ratio NextCure|NXTC - Company Long-Term Debt|Short-Term Debt NextCure|Critical Liquidity nextcure.com
- company profitability and valuation multiples indicators:
NXTC - Net Income|Future Net Profit NextCure, Inc.|NXTC - P/E Multiple|Future Price to Earnings Multiple nextcure.com|NXTC - PEG Multiple|Company Value to EBITDA NextCure|NXTC - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year NextCure|NXTC - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth nextcure.com|NXTC - Earnings per share growth in current year|Net earnings per share change forecast for next year NextCure, Inc.
Analysis of all company metrics:NextCure Corporation - NXTC
Mass-produced product of NextCure

This indicator measures the operational efficiency of the business, excluding the impact of depreciation and taxes to assess the company's ability to generate real cash flow. By analyzing the EBITDA cash volume, an investor can see the resilience of the NextCure, Inc. (NXTC) commercial model against geopolitical risks, which hinder the international certification of innovative cancer therapy drugs through supply chain disruptions and sanctions.

Competitors of NextCure, Inc. (NXTC)

NantKwest (IBRX) - Profit before interest, taxes and amortization|IMCR: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization JANX (januxrx.com)|RCUS: Operating profit EBITDA|ZYME - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Tango Pharma|Operating profit before deduction of amortization Iovance Corp (IOVA)|Profit before payment of interest, taxes and amortization Immatics N.V. (IMTX)|Operating profit before deduction of amortization xencor.com XNCR|Compass Therapeutics, Inc. - Operating profit before deduction of amortization|Operating profit EBITDA Replimune Group Inc REPL|LYEL - Profit before payment of interest, taxes and amortization|IPHA (Innate Pharma S.A) - Operating profit before amortization|pyxisoncology.com (PYXS) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Compugen (CGEN)|Operating profit before deduction of amortization IOBT|STRO - Operating profit before depreciation charges|Operating profit before deduction of amortization INKT (MiNK)|Company profit before taxes, interest and amortization HOWL|Operating profit EBITDA IMMX (Immix Biopharma)|Income before deduction of interest, taxes and amortization ALXO|Cue Biopharma, Inc. - Operating profit EBITDA|Profit before interest, taxes and amortization PDS Biotechnology|sonnetbio.com (SONN) - Profit before payment of interest, taxes and amortization|MAIA Bio - Income before deduction of interest, taxes and amortization|LIMN (Liminatus Pharma) - Operating profit EBITDA|Operating profit EBITDA Lava Tx|Profit before payment of interest, taxes and amortization Leap Therapeutics, Inc. (LPTX)|INTS: Profit before deduction of interest, taxes, depreciation and amortization|Sensei Biotherapeutics, Inc. - Operating profit before deduction of amortization|Theriva Corp (TOVX) - Profit before interest, taxes and amortization|GRTS - Profit before payment of interest, taxes and amortization|KA (kinetabio.com) - Operating profit before amortization|NEXI: Operating profit EBITDA|Profit before interest, taxes and amortization Turnstone Biologics Corp. (TSBX)|Operating profit before deduction of amortization VCNX|Operating profit before amortization HARP (Harpoon Therapeutics Corp)